Oncolytics net loss widens to $9.44 million in Q2 2026; R&D expenses more than doubled to $4.26 million - ONCY News | RalliesOncolytics net loss widens to $9.44 million in Q2 2026; R&D expenses more than doubled to $4.26 million
O
ONCY• Program updates
- The company launched REO 033 in March and expects about half of planned sites to be activated in Q3.
- Oncolytics also said it has Fast Track designations in mCRC and SCAC.
Q2 loss widens as R&D and G&A rise
- Oncolytics Biotech posted a Q2 net loss of USD 9.44 million, widening from USD 5.28 million a year earlier.
- R&D expense more than doubled to USD 4.26 million, driven by Phase 2 second-line mCRC start-up costs and higher stock-based pay.
- G&A expense rose 87.1% to USD 5.12 million on higher investor relations activity and added legal and tax fees tied to domestication.
Cash position and going-concern warning
- Cash and cash equivalents totaled USD 4.12 million at June 30, 2026; management flagged substantial doubt about going concern.
